The latest price target for Hoth Therapeutics (NASDAQ:HOTH) was reported by EF Hutton on September 5, 2024. The analyst firm set a price target for $5.00 expecting HOTH to rise to within 12 months (a possible 390.20% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Hoth Therapeutics (NASDAQ:HOTH) was provided by EF Hutton, and Hoth Therapeutics maintained their buy rating.

There is no last upgrade for Hoth Therapeutics

There is no last downgrade for Hoth Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hoth Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hoth Therapeutics was filed on September 5, 2024 so you should expect the next rating to be made available sometime around September 5, 2025.

While ratings are subjective and will change, the latest Hoth Therapeutics (HOTH) rating was a maintained with a price target of $5.00 to $5.00. The current price Hoth Therapeutics (HOTH) is trading at is $1.02, which is out of the analyst’s predicted range.